Literature DB >> 33591187

CC Chemokine Receptor 5 Targeted Nanoparticles Imaging the Progression and Regression of Atherosclerosis Using Positron Emission Tomography/Computed Tomography.

Lisa Detering1, Allison Abdilla2, Hannah P Luehmann1, Jesse W Williams3, Li-Hao Huang3, Deborah Sultan1, Andrew Elvington3, Gyu Seong Heo1, Pamela K Woodard1, Robert J Gropler1, Gwendalyn J Randolph3, Craig J Hawker2, Yongjian Liu1.   

Abstract

Chemokines and chemokine receptors play an important role in the initiation and progression of atherosclerosis by mediating the trafficking of inflammatory cells. Chemokine receptor 5 (CCR5) has major implications in promoting the development of plaques to advanced stage and related vulnerability. CCR5 antagonist has demonstrated the effective inhibition of atherosclerotic progression in mice, making it a potential biomarker for atherosclerosis management. To accurately determine CCR5 in vivo, we synthesized CCR5 targeted Comb nanoparticles through a modular design and construction strategy with control over the physiochemical properties and functionalization of CCR5 targeting peptide d-Ala-peptide T-amide (DAPTA-Comb). In vivo pharmacokinetic evaluation through 64Cu radiolabeling showed extended blood circulation of 64Cu-DAPTA-Combs conjugated with 10%, 25%, and 40% DAPTA. The different organ distribution profiles of the three nanoparticles demonstrated the effect of DAPTA on not only physicochemical properties but also targeting efficiency. In vivo positron emission tomography/computed tomography (PET/CT) imaging in an apolipoprotein E knockout mouse atherosclerosis model (ApoE-/-) showed that the three 64Cu-DAPTA-Combs could sensitively and specifically detect CCR5 along the progression of atherosclerotic lesions. In an ApoE-encoding adenoviral vector (AAV) induced plaque regression ApoE-/- mouse model, decreased monocyte recruitment, CD68+ macrophages, CCR5 expression, and plaque size were all associated with reduced PET signals, which not only further confirmed the targeting efficiency of 64Cu-DAPTA-Combs but also highlighted the potential of these targeted nanoparticles for atherosclerosis imaging. Moreover, the up-regulation of CCR5 and colocalization with CD68+ macrophages in the necrotic core of ex vivo human plaque specimens warrant further investigation for atherosclerosis prognosis.

Entities:  

Keywords:  CCR5; atherosclerosis; macrophage; nanoparticle; positron emission tomography

Mesh:

Substances:

Year:  2021        PMID: 33591187      PMCID: PMC8737066          DOI: 10.1021/acs.molpharmaceut.0c01183

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  46 in total

Review 1.  Noninvasive Imaging to Assess Atherosclerotic Plaque Composition and Disease Activity: Coronary and Carotid Applications.

Authors:  Marwa Daghem; Rong Bing; Zahi A Fayad; Marc R Dweck
Journal:  JACC Cardiovasc Imaging       Date:  2019-08-14

Review 2.  Chemokine receptor CCR5: from AIDS to atherosclerosis.

Authors:  K L Jones; J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 3.  Evolving Role of PET in Detecting and Characterizing Atherosclerosis.

Authors:  Poul Flemming Høilund-Carlsen; Mateen C Moghbel; Oke Gerke; Abass Alavi
Journal:  PET Clin       Date:  2019-04

4.  Novel candidate genes in unstable areas of human atherosclerotic plaques.

Authors:  Marianna Papaspyridonos; Alberto Smith; Kevin G Burnand; Peter Taylor; Soundrie Padayachee; Keith E Suckling; Christian H James; David R Greaves; Lisa Patel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-06-01       Impact factor: 8.311

5.  PET/CT Imaging of Chemokine Receptors in Inflammatory Atherosclerosis Using Targeted Nanoparticles.

Authors:  Hannah P Luehmann; Lisa Detering; Brett P Fors; Eric D Pressly; Pamela K Woodard; Gwendalyn J Randolph; Robert J Gropler; Craig J Hawker; Yongjian Liu
Journal:  J Nucl Med       Date:  2016-01-21       Impact factor: 10.057

6.  Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice.

Authors:  Sabrina Cipriani; Daniela Francisci; Andrea Mencarelli; Barbara Renga; Elisabetta Schiaroli; Claudio D'Amore; Franco Baldelli; Stefano Fiorucci
Journal:  Circulation       Date:  2013-04-30       Impact factor: 29.690

7.  A possible role for CCR5 in the progression of atherosclerosis in HIV-infected patients: a cross-sectional study.

Authors:  Laura Fernández-Sender; Carlos Alonso-Villaverde; Anna Rull; Esther Rodríguez-Gallego; Marta Riera-Borrull; Anna Hernández-Aguilera; Jordi Camps; Raúl Beltrán-Debón; Gerard Aragonès; Javier A Menendez; Jorge Joven
Journal:  AIDS Res Ther       Date:  2013-05-09       Impact factor: 2.250

Review 8.  Positron emission tomography imaging of atherosclerosis.

Authors:  Hakan Orbay; Hao Hong; Yin Zhang; Weibo Cai
Journal:  Theranostics       Date:  2013-11-02       Impact factor: 11.556

9.  Local proliferation dominates lesional macrophage accumulation in atherosclerosis.

Authors:  Clinton S Robbins; Ingo Hilgendorf; Georg F Weber; Igor Theurl; Yoshiko Iwamoto; Jose-Luiz Figueiredo; Rostic Gorbatov; Galina K Sukhova; Louisa M S Gerhardt; David Smyth; Caleb C J Zavitz; Eric A Shikatani; Michael Parsons; Nico van Rooijen; Herbert Y Lin; Mansoor Husain; Peter Libby; Matthias Nahrendorf; Ralph Weissleder; Filip K Swirski
Journal:  Nat Med       Date:  2013-08-11       Impact factor: 53.440

10.  Harnessing 64Cu/67Cu for a theranostic approach to pretargeted radioimmunotherapy.

Authors:  Outi Keinänen; Kimberly Fung; James M Brennan; Nicholas Zia; Matt Harris; Ellen van Dam; Colin Biggin; Amos Hedt; Jon Stoner; Paul S Donnelly; Jason S Lewis; Brian M Zeglis
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-26       Impact factor: 12.779

View more
  3 in total

Review 1.  Surface-modified nanotherapeutics targeting atherosclerosis.

Authors:  Wenpan Li; Karina Marie Gonzalez; Jinha Chung; Minhyeok Kim; Jianqin Lu
Journal:  Biomater Sci       Date:  2022-09-27       Impact factor: 7.590

Review 2.  Advances in Radiopharmaceutical Sciences for Vascular Inflammation Imaging: Focus on Clinical Applications.

Authors:  Kevin Prigent; Jonathan Vigne
Journal:  Molecules       Date:  2021-11-24       Impact factor: 4.411

3.  PCSK9 Imperceptibly Affects Chemokine Receptor Expression In Vitro and In Vivo.

Authors:  Sai Sahana Sundararaman; Linsey J F Peters; Sumra Nazir; Andrea Bonnin Marquez; Janneke E Bouma; Soyolmaa Bayasgalan; Yvonne Döring; Emiel P C van der Vorst
Journal:  Int J Mol Sci       Date:  2021-12-01       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.